Exosome Integrin Profiling for Organ-Specific Metastasis Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods have limited progress in decoding the mechanisms governing organ-specific metastasis and lack effective diagnostic and therapeutic tools for predicting and preventing cancer metastasis to specific organs.
Innovation Solution
The use of tumor-derived exosomes expressing specific integrins to direct organ-specific colonization and the development of kits and methods for detecting these integrins to predict metastatic sites, allowing for personalized therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional metastasis research methods are used, then understanding of general metastasis mechanisms is achieved, but organ-specific metastasis mechanisms remain poorly decoded
Solution Approach 1:
The invention segments metastasis research into organ-specific categories by identifying distinct integrin profiles (e.g., αvβ3 for brain, α6β4 for lung, αvβ5 for liver) that direct cancer cells to specific organs. This segmentation allows precise decoding of organ-specific mechanisms rather than treating metastasis as a general process.
Solution Approach 2:
The invention uses tumor-derived exosomes as intermediaries to deliver organ-specific integrins to distant sites. These exosomes act as mediators that carry the metastatic program from primary tumors to specific organs, enabling non-invasive detection and prediction of metastatic sites.
2Adaptability or versatility
If general cancer treatment approaches are used, then overall cancer management is provided, but personalized prevention of organ-specific metastasis is not achieved
Solution Approach 1:
The invention enables preliminary action by detecting organ-specific integrin profiles in circulating exosomes before metastasis occurs. This early detection allows clinicians to administer targeted therapeutics (e.g., integrin inhibitors like cilengitide for brain metastasis prevention) to prevent metastasis before it develops, rather than waiting for clinical evidence of spread.
Solution Approach 2:
The invention applies local quality by matching specific integrin inhibitors to specific organ metastasis risks based on detected integrin profiles. For example, αvβ3-positive patients receive brain metastasis prevention therapy, while α6β4-positive patients receive lung metastasis prevention therapy, providing localized personalized prevention rather than general treatment.
3Measurement precision
If invasive biopsy methods are used for metastasis detection, then accurate diagnosis is achieved, but patient morbidity and treatment complexity increase
Solution Approach 1:
The invention uses circulating exosomes as non-invasive copies or proxies for tumor cells. These exosomes carry the same organ-specific integrin profiles as the parent tumor cells, allowing accurate prediction of metastatic sites through simple blood tests rather than invasive biopsies or imaging procedures.
Solution Approach 2:
The invention uses circulating exosomes as intermediaries that bridge the gap between non-invasive sampling and accurate metastasis detection. These exosomes serve as messenger molecules that convey tumor-specific information about organ tropism from the primary site to distant organs, detectable in peripheral blood.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and prevention of metastasis, optimizes treatment, and provides a non-invasive diagnostic and prognostic tool for predicting metastatic sites, improving cancer patient stratification and treatment outcomes.
Implementation Method 1
tumor-derived exosomes expressing specific integrins to direct organ-specific colonization
Data Source
AI summary
The present invention relates to methods and kits for prognosing, treating, and managing treatment of cancer in a subject. The methods involve selecting a subject having cancer and obtaining, from the selected subject, a sample containing exosomes or an S100 molecule containing sample. The exosomes or S100 molecule containing sample, respectively, are then contacted with one or more reagents suitable to detect higher or lower levels or the presence or absence of one or more integrins on said exosomes or higher or lower levels or the presence or absence of one or more S100 molecules in the S100 molecule containing sample. The cancer is then prognosed, treatment is administered, or treatment is managed.